Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study.

ABSTRACT:

Background

To evaluate the efficacy and safety of cabozantinib in Japanese patients with advanced hepatocellular carcinoma (HCC) who had progressed following one or two lines of systemic therapy including sorafenib. An exploratory evaluation in sorafenib-naïve patients was performed.

Methods

In this open-label, single-arm, phase 2 trial, patients received oral cabozantinib 60 mg once daily. The primary endpoint was progression-free survival (PFS) rate at Week 24. Secondary endpoints included PFS, overall survival (OS), objective response rate (ORR, best response of complete/partial response), disease control rate (DCR, objective response or stable disease) and safety.

Results

Thirty-four patients received cabozantinib across 17 centers (prior sorafenib cohort, n = 20;

SUBMITTER: Kudo M 

PROVIDER: S-EPMC7862203 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature